AR048675A1 - Derivados de 1-(1h-indol- 1-il)- 3- (4-metilpiperazin-1-il)-1- fenil propan 2 ol - Google Patents
Derivados de 1-(1h-indol- 1-il)- 3- (4-metilpiperazin-1-il)-1- fenil propan 2 olInfo
- Publication number
- AR048675A1 AR048675A1 ARP050101217A ARP050101217A AR048675A1 AR 048675 A1 AR048675 A1 AR 048675A1 AR P050101217 A ARP050101217 A AR P050101217A AR P050101217 A ARP050101217 A AR P050101217A AR 048675 A1 AR048675 A1 AR 048675A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- ring
- occurrence
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Una sal farmacéuticamente aceptable de los mismos, composiciones que contienen estos derivados y los métodos de uso para la prevencion y tratamiento de afecciones que mejoran con la recaptacion de monoaminas como son, inter alia, los síntomas vasomotores (SVM), la disfuncion sexual, trastornos gastrointestinales y genitourinarios, síndrome de fatiga cronica, síndrome de fibromialgia, trastornos del sistema nervioso y combinaciones de las mismas, en particular aquellas afecciones seleccionadas entre el grupo formado por un trastorno depresivo mayor, los síntomas vasomotores, incontinencia urinaria por esfuerzo y por urgencia, fibromialgia, dolor, neuropatía diabética y combinaciones de las mismas. Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo; en donde: la línea de puntos entre Y y Z representa un doble enlace opcional; la línea de puntos entre los dos grupos R4 representa un anillo heterocíclico opcional de 4 a 6 átomos en el anillo que se puede formar entre los dos grupos R4, junto al nitrogeno a través del cual se forma el enlace; Y es N, CR6 o C=O; Z es N, NR7, CR5 o C(R5)2; R1 es, de forma independiente en cada aparicion, alquilo, alcoxi, halo, CF3, OCF3, arilalquiloxi sustituido con 0-3 R11, ariloxi sustituido con 0-3 R11, arilo sustituido con 0-3 R11, heteroarilo sustituido con 0-3 R11, hidroxi, alcanoiloxi, nitro, nitrilo, alquenilo, alquinilo, alquilsulfoxido, fenilsulfoxido sustituido con 0-3 R11, alquilsulfona, fenilsulfona sustituida con 0-3 R11, alquilsulfonamida, fenilsulfonamida sustituida con 0-3 R11, heteroariloxi sustituido con 0-3 R11, heteroarilmetiloxi sustituido con 0-3 R11, alquilamida o arilamida sustituida con 0-3 R11; o dos R1 adyacentes también representan metilendioxi; R2 es arilo sustituido con 0-3 R1 o heteroarilo sustituido con 0-3 R1; R3 es H o alquilo C1-4; R4 es, de forma independiente en cada aparicion, H, alquilo C1-4, arilalquilo, heteroarilmetilo, cicloheptilmetilo, ciclohexilmetilo, ciclopentilmetilo o ciclobutilmetilo, o ambos grupos R4, junto al nitrogeno a través del cual se forma el enlace, forman un anillo heterocíclico de 4 a 6 átomos en el anillo, en donde un carbono puede remplazarse opcionalmente con N, O, S o SO2 y en donde cualquier átomo del anillo de carbono o un átomo de N adicional pueden estar opcionalmente sustituidos con alquilo C1-4, F o CF3; R5 es, de forma independiente en cada aparicion, H, alquilo C1-4, arilo sustituido con 0-3 R1 o ciano; o cuando hay dos R5, forman un anillo carbocíclico de 3-7 carbonos; R6 es H, alquilo C1-4 o ciano; R7 es H, alquilo C1-6, cicloalquilo C3-6 o arilo sustituido con 0-3 R1; R8 es H o alquilo C1-4; R9 es H o alquilo C1-4; R10 es, de forma independiente en cada aparicion, H o alquilo C1-4; o R10 y R4 junto al nitrogeno al cual se une R4 forman un anillo que contiene nitrogeno que contiene 3-6 átomos de carbono; n es un numero entero 0 y 4; x es un numero entero entre 1 y 2; y R11 es alquilo, alcoxi, halo, CF3, OCF3, hidroxi, alcanoiloxi, nitro, nitrilo, alquenilo, alquinilo, alquilsulfoxido, alquilsulfona, alquilsulfonamida o alquilamida; o dos R11 adyacentes también representan metilendioxi; en donde 1-3 átomos de carbono en el anillo A pueden reemplazarse opcionalmente con N
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55765104P | 2004-03-30 | 2004-03-30 | |
US56986304P | 2004-05-11 | 2004-05-11 | |
US11/091,885 US7517899B2 (en) | 2004-03-30 | 2005-03-28 | Phenylaminopropanol derivatives and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048675A1 true AR048675A1 (es) | 2006-05-17 |
Family
ID=34964018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101217A AR048675A1 (es) | 2004-03-30 | 2005-03-30 | Derivados de 1-(1h-indol- 1-il)- 3- (4-metilpiperazin-1-il)-1- fenil propan 2 ol |
Country Status (20)
Country | Link |
---|---|
US (3) | US7517899B2 (es) |
EP (1) | EP1732887B1 (es) |
JP (1) | JP2007531751A (es) |
KR (1) | KR20060134186A (es) |
AR (1) | AR048675A1 (es) |
AT (1) | ATE383337T1 (es) |
AU (1) | AU2005230900A1 (es) |
BR (1) | BRPI0509390A (es) |
CA (1) | CA2560967A1 (es) |
CR (1) | CR8639A (es) |
DE (1) | DE602005004268T2 (es) |
DK (1) | DK1732887T3 (es) |
EC (1) | ECSP066899A (es) |
ES (1) | ES2299025T3 (es) |
IL (1) | IL178185A0 (es) |
NO (1) | NO20064892L (es) |
PE (1) | PE20060288A1 (es) |
PL (1) | PL1732887T3 (es) |
TW (1) | TW200536532A (es) |
WO (1) | WO2005097744A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7414052B2 (en) * | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
JP4698671B2 (ja) * | 2004-06-01 | 2011-06-08 | エフ.ホフマン−ラ ロシュ アーゲー | モノアミン再取り込み阻害剤としての3−アミノ−1−アリールプロピルインドール |
MX2007013450A (es) * | 2005-04-29 | 2008-01-21 | Wyeth Corp | Procedimniento de preparacion de oxindoles y tio-oxindoles 3,3-disustituidos. |
US20070072897A1 (en) * | 2005-09-29 | 2007-03-29 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
TW200800888A (en) * | 2005-09-29 | 2008-01-01 | Wyeth Corp | Substituted propylamine derivatives and methods of their use |
EP1957454B1 (en) | 2005-11-30 | 2011-07-20 | F. Hoffmann-La Roche AG | Methods for synthesis of 3-amino-1-arylpropyl indoles |
CN101316818B (zh) * | 2005-11-30 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 3-氨基-1-芳基丙基吲哚类和氮杂取代的吲哚类 |
EP1957488B1 (en) * | 2005-11-30 | 2009-09-09 | F.Hoffmann-La Roche Ag | 3-amino-2-arylpropyl azaindoles and uses thereof |
TW200817382A (en) * | 2006-08-24 | 2008-04-16 | Wyeth Corp | Process for preparing indolinone phenylaminopropanol derivatives |
US7671238B2 (en) * | 2006-10-04 | 2010-03-02 | Wyeth Llc | Arylamino-arylpropanolamine derivatives and methods of their use |
HUP1000598A2 (en) | 2010-11-05 | 2012-09-28 | Richter Gedeon Nyrt | Indole derivatives |
WO2012097744A1 (en) | 2011-01-20 | 2012-07-26 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
LT2875013T (lt) | 2012-07-17 | 2018-02-26 | Glaxosmithkline Intellectual Property (No. 2) Limited | Indolkarbonitrilai, kaip selektyvūs androgeno receptoriaus moduliatoriai |
KR101460738B1 (ko) * | 2012-08-23 | 2014-11-12 | 한국과학기술연구원 | 신규한 2-나프틸 프로판-2-올 화합물, 이를 포함하는 약학 조성물, 및 상기 약학 조성물을 포함하는 제제 |
MX2021000043A (es) | 2018-07-03 | 2021-03-25 | Univ Illinois | Activadores de la respuesta a proteinas desplegadas. |
US20220296604A1 (en) * | 2019-08-08 | 2022-09-22 | New York University | Indole compounds as modulators of rage activity and uses thereof |
CN114539080A (zh) * | 2022-03-02 | 2022-05-27 | 八叶草健康产业研究院(厦门)有限公司 | 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3454554A (en) * | 1960-10-14 | 1969-07-08 | Colgate Palmolive Co | Aminoalkyliminodibenzyl compounds |
US4123543A (en) * | 1971-09-16 | 1978-10-31 | Ab Kabi | Derivatives of substituted indoline lactans with effect on the central nervous system |
CS175831B1 (es) | 1974-12-17 | 1977-05-31 | ||
IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
US4310524A (en) * | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
PH18686A (en) | 1981-05-26 | 1985-08-29 | Merck & Co Inc | 1-(3 halo-2-pyridinyl) piperazine |
US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
EP0135905A3 (de) | 1983-09-29 | 1986-10-22 | ASTA Pharma Aktiengesellschaft | Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane |
CA1280421C (en) | 1985-07-02 | 1991-02-19 | Albert A. Carr | 1,4-disubstituted piperidinyl derivatives |
ZA885824B (en) | 1987-08-14 | 1989-04-26 | Merrell Dow Pharma | Novel antidepressants |
US4826844A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols |
ATE114467T1 (de) | 1990-06-01 | 1994-12-15 | Merrell Dow Pharma | (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol. |
US5648511A (en) * | 1990-11-19 | 1997-07-15 | G.D. Searle & Co. | Method for making intermediates useful in the synthesis of retroviral protease inhibitors |
FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
US5502047A (en) * | 1993-03-22 | 1996-03-26 | Kavey; Neil B. | Treatment for insomnia |
US5516774A (en) * | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
FR2714378B1 (fr) | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
WO1996005818A1 (en) | 1994-08-19 | 1996-02-29 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
AU5857296A (en) | 1995-05-17 | 1996-11-29 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
GB9606016D0 (en) * | 1996-03-22 | 1996-05-22 | Smithkline Beecham Plc | Novel use |
CN1494907A (zh) | 1996-03-25 | 2004-05-12 | 治疗疼痛的药物组合物 | |
WO1998014208A1 (en) | 1996-09-30 | 1998-04-09 | President And Fellows Of Harvard College | Reactive ligands and covalent ligand-protein complexes |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
TR200002507T2 (tr) | 1998-03-02 | 2000-12-21 | Eli Lilly And Company | Ateş basmasını azaltmak için fluoksetin hidroklorür |
TW528754B (en) | 1998-04-29 | 2003-04-21 | Wyeth Corp | Indolyl derivatibes as serotonergic agents |
AU771252B2 (en) | 1998-07-13 | 2004-03-18 | Nps Pharmaceuticals, Inc. | Methods and compounds for treating depression and other disorders |
EP1905757A1 (en) | 1999-04-06 | 2008-04-02 | Sepracor Inc. | Derivatives of Venlafaxine and methods of preparing and using the same |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
ES2246485T3 (es) * | 1999-07-01 | 2006-02-16 | PHARMACIA & UPJOHN COMPANY LLC | (s,s)-reboxetina para tratar la incontinencia. |
FR2804115B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2804114B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
AU2001249397A1 (en) | 2000-03-24 | 2001-10-08 | Cor Therapeutics, Inc. | Oxindole inhibitors of factor xa |
US20030008860A1 (en) * | 2002-05-09 | 2003-01-09 | Bakker-Arkema Rebecca Guggemos | Treatment of congestive heart failure |
GB2362826A (en) | 2000-06-02 | 2001-12-05 | Lilly Co Eli | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist |
US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
AU9087301A (en) | 2000-09-11 | 2002-03-26 | Sepracor Inc | Ligands for monoamine receptors and transporters, and methods of use thereof |
US6673838B2 (en) | 2001-02-12 | 2004-01-06 | Wyeth | Succinate salt of O-desmethyl-venlafaxine |
EP1383495A1 (en) | 2001-03-29 | 2004-01-28 | Eli Lilly And Company | Duloxetine for treatment of hot flashes |
EP1266659A1 (en) | 2001-06-11 | 2002-12-18 | Pantarhei Bioscience B.V. | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes |
WO2003010169A1 (en) | 2001-07-25 | 2003-02-06 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 7, 8-dihydro-6h-5-oxa-1-aza-phenanthrene |
WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
WO2003037334A1 (en) | 2001-10-31 | 2003-05-08 | Merck & Co., Inc. | Method for treating or preventing symptoms of hormonal variation including hot flashes |
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
ES2399880T3 (es) | 2002-03-15 | 2013-04-04 | Cypress Bioscience, Inc. | Milnaciprán para el tratamiento del síndrome del intestino irritable |
TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
CN1674907A (zh) | 2002-08-14 | 2005-09-28 | 法玛西亚普强责任有限公司 | 瑞波西汀在治疗热潮红中的用途 |
US7345096B2 (en) * | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
US20040152710A1 (en) * | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
US20040180879A1 (en) * | 2002-10-15 | 2004-09-16 | Deecher Darlene Coleman | Novel method of treating vasomotor symptoms |
US7491723B2 (en) * | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
US20050130987A1 (en) * | 2003-10-14 | 2005-06-16 | Wyeth | Methods of treating vasomotor symptoms |
US7550485B2 (en) * | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
US7524846B2 (en) * | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
US7365076B2 (en) * | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
US7419980B2 (en) * | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
US7531543B2 (en) * | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
US20050165082A1 (en) * | 2003-12-16 | 2005-07-28 | Wyeth | Methods of treating vasomotor symptoms |
US7414052B2 (en) * | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
-
2005
- 2005-03-28 US US11/091,885 patent/US7517899B2/en not_active Expired - Fee Related
- 2005-03-29 JP JP2007506469A patent/JP2007531751A/ja not_active Withdrawn
- 2005-03-29 TW TW094109747A patent/TW200536532A/zh unknown
- 2005-03-29 KR KR1020067022665A patent/KR20060134186A/ko not_active Application Discontinuation
- 2005-03-29 AT AT05730271T patent/ATE383337T1/de not_active IP Right Cessation
- 2005-03-29 ES ES05730271T patent/ES2299025T3/es active Active
- 2005-03-29 PL PL05730271T patent/PL1732887T3/pl unknown
- 2005-03-29 EP EP05730271A patent/EP1732887B1/en active Active
- 2005-03-29 BR BRPI0509390-2A patent/BRPI0509390A/pt not_active IP Right Cessation
- 2005-03-29 WO PCT/US2005/010511 patent/WO2005097744A1/en active IP Right Grant
- 2005-03-29 AU AU2005230900A patent/AU2005230900A1/en not_active Withdrawn
- 2005-03-29 DE DE602005004268T patent/DE602005004268T2/de not_active Expired - Fee Related
- 2005-03-29 DK DK05730271T patent/DK1732887T3/da active
- 2005-03-29 CA CA002560967A patent/CA2560967A1/en not_active Abandoned
- 2005-03-30 PE PE2005000365A patent/PE20060288A1/es not_active Application Discontinuation
- 2005-03-30 AR ARP050101217A patent/AR048675A1/es unknown
-
2006
- 2006-09-19 IL IL178185A patent/IL178185A0/en unknown
- 2006-09-20 CR CR8639A patent/CR8639A/es not_active Application Discontinuation
- 2006-09-29 EC EC2006006899A patent/ECSP066899A/es unknown
- 2006-10-26 NO NO20064892A patent/NO20064892L/no not_active Application Discontinuation
-
2008
- 2008-12-15 US US12/335,144 patent/US20090099164A1/en not_active Abandoned
- 2008-12-15 US US12/335,245 patent/US20090093469A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1732887A1 (en) | 2006-12-20 |
DE602005004268D1 (de) | 2008-02-21 |
DK1732887T3 (da) | 2008-04-28 |
EP1732887B1 (en) | 2008-01-09 |
ECSP066899A (es) | 2006-11-24 |
PE20060288A1 (es) | 2006-05-23 |
US20090093469A1 (en) | 2009-04-09 |
CA2560967A1 (en) | 2005-10-20 |
WO2005097744A1 (en) | 2005-10-20 |
IL178185A0 (en) | 2006-12-31 |
US7517899B2 (en) | 2009-04-14 |
JP2007531751A (ja) | 2007-11-08 |
DE602005004268T2 (de) | 2009-01-02 |
ATE383337T1 (de) | 2008-01-15 |
BRPI0509390A (pt) | 2007-09-18 |
ES2299025T3 (es) | 2008-05-16 |
US20050222148A1 (en) | 2005-10-06 |
CR8639A (es) | 2007-06-08 |
US20090099164A1 (en) | 2009-04-16 |
KR20060134186A (ko) | 2006-12-27 |
AU2005230900A1 (en) | 2005-10-20 |
TW200536532A (en) | 2005-11-16 |
PL1732887T3 (pl) | 2008-05-30 |
NO20064892L (no) | 2006-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048675A1 (es) | Derivados de 1-(1h-indol- 1-il)- 3- (4-metilpiperazin-1-il)-1- fenil propan 2 ol | |
AR056544A1 (es) | Derivados fenilaminopropanol y metodos de uso de los mismos | |
AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
AR048447A1 (es) | Derivados fenilaminopropanol, composiciones farmaceuticas que los contienen y usos como moduladores de la recaptacion de monoaminas | |
AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
AR068511A1 (es) | Tetrahidro[1,4'] bipiridinil-2'-onas sustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
EA200501327A1 (ru) | Пиримидины и триазины, ингибирующие вич репликацию | |
AR048454A1 (es) | Azaindoles utiles como inhibidores de las proteinas quinasas jak u otras proteinas quinasas | |
PE20091100A1 (es) | Nuevos compuestos 010 | |
UY26020A1 (es) | Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc. | |
AR058296A1 (es) | Inhibidores de histona desacetilasa y composicion farmaceutica | |
AR070861A1 (es) | Uso de terapia de combinacion con antagonistas de c-met y egfr | |
PA8607001A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
UY28833A1 (es) | Piridonas sustituidas como inhibidores de poli (adp-ribosa)-polimerasa (parp). | |
AR056560A1 (es) | Pirrolopiridinonas como moduladores cb1 | |
TW200745058A (en) | MMP-13 selective inhibitors | |
AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos | |
UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
ES2193875B2 (es) | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. | |
AR041697A1 (es) | Piperazinil y diazepanil benzamidas y benzotiamidas; composiciones farmaceuticas que las contienen y su uso para la fabricacion de un medicamento | |
AR052308A1 (es) | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto | |
AR016644A1 (es) | Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos | |
GT200700084A (es) | Derivados de indanil-piperazinas, su procedimiento de preparación y las composiciones farmaceuticas que los contienen. | |
AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |